Start-Ups Look For Places In Future HCV Combo Regimens
This article was originally published in Start Up
Executive SummaryWith more than 50 drugs in development for hepatitis C, what comes next after first-generation protease inhibitors and what opportunity might there be for small start-up firms in a space where so many Big Pharma and specialty pharma companies are active? Approvals of direct-acting antiviral therapies are just around the corner in hepatitis C, and smaller companies are looking to provide parts of the puzzle in next-generation drug cocktails that will tackle the growing disease. However, in order for small companies to succeed in this highly competitive space they'll need highly differentiated products. START-UP profiles AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus.
You may also be interested in...
BioCryst’s proposed merger with Presidio will give the company an instant HCV pipeline. Albeit early-stage, the variety of the drugs could give the company a strong hand against other players in the field.